scholarly journals Impact of Gender: Female Matched Related Donor Versus Male Matched Unrelated Donor on Peripheral Blood Allogeneic Stem Cell Transplant for Male Recipients

2015 ◽  
Vol 21 (2) ◽  
pp. S281-S282 ◽  
Author(s):  
Shatha Farhan ◽  
Edward Peres ◽  
Danielle Pelland ◽  
Susan Wautelet ◽  
Klodiana Neme ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Stem Cell Transplant ◽  
Unrelated Donor ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Matched Unrelated Donor ◽  
Related Donor

Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant

2017 ◽  
Vol 99 (3) ◽  
pp. 275-282 ◽  
Author(s):  
Ann M. Moyer ◽  
Shahrukh K. Hashmi ◽  
Cynthia M. Kroning ◽  
Walter K. Kremers ◽  
Steven R. De Goey ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Outcomes ◽  
Stem Cell Transplant ◽  
Unrelated Donor ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Matched Unrelated Donor

Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?

2018 ◽  
Vol 79 (7) ◽  
pp. 532-536 ◽  
Author(s):  
Ann M. Moyer ◽  
Shahrukh K. Hashmi ◽  
Cynthia Kroning ◽  
Steven R. De Goey ◽  
Mrinal Patnaik ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplant ◽  
Unrelated Donor ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Matched Unrelated Donor

The Transplant Outcomes of a 10/10 Matched Unrelated Donor (MUD) Stem Cell Transplant (SCT) Is Similar to a HLA Identical Related Donor (RD) Transplant.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4346-4346
Author(s):  
Catherine Veeder ◽  
Sheila Davies ◽  
Christina Havey ◽  
John J. Maciejewski ◽  
Sunita Nathan ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hodgkin Lymphoma ◽  
Myeloid Leukemia ◽  
Stem Cell Transplant ◽  
Hla Typing ◽  
Unrelated Donor ◽  
Cell Transplant ◽  
Matched Unrelated Donor ◽  
Related Donor

Abstract Abstract 4346 Background Allogeneic SCT is a potential curative treatment for many hematological malignancies. Unfortunately, approximately 70% of patients who may benefit from an allogeneic SCT can not find a HLA identical related donor. Through National Marrow Donor Program, about 60-70% patients will be able to identify a suitable donor for transplant. However, prior studies suggested that MUD-SCT was associated with increased transplant related morbidity and mortality when compared with RD-SCT. Hence, many hematologists/oncologists were hesitant to recommend a MUD-SCT even when a matched related donor is not available. We hypothesized that through optimal HLA typing and using a 10/10 molecularly matched unrelated donor, the outcomes for a MUD-SCT will be similar to RD-SCT. Method Beginning in 2004, we adopted a new policy in HLA typing and all patients and donors will be tested for HLA: A, B, C, DR, and DQ using molecular techniques. Here, we report the outcomes on 24 consecutive patients who revived a 10/10 MUD-BMT at our institution. Results Between February, 2004 and April, 2008, 24 patients (8 males & 16 females) with various hematological malignancy and life threatening hematological disorders underwent a 10/10 molecularly matched MUD-SCT at Rush University Medical Center. Median age at SCT was 43 (range 18-67). Diagnoses included acute myeloid leukemia:11, myelodysplasia:3, non-hodgkin lymphoma:3, chronic myeloid leukemia:2, acute lymphoblastic leukemia:2, severe aplastic anemia:2 and hodgkin lymphoma:1. While 9/24 (38%) has early disease, 15/24 (62%) had advanced disease at SCT. All patients received a myeloablative conditioning regimen. Four patients (4/24, 17%) died before day 100 post-SCT from treatment related toxicity; all 4 pts > 55 years old. The 1-year survival was 62.5% with a minimal follow-up of 1 year for surviving patients. At last follow-up, 9 patients survived greater than 3 years post-SCT. The cumulative incidences of acute GVHD Grades ≥ 2 and 3 - 4 were 42% and 13% respectively. Conclusion We conclude that the transplant outcomes of 10/10 matched unrelated donor stem cell transplant appears similar to matched related donor stem cell transplant. Thus, matched related donor stem cell transplant should be considered for patients lacking a HLA identical donor whenever an allogeneic SCT is clinically indicated. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Impact of Gender: Female Related Donor Versus Male Matched Unrelated Donor on Peripheral Blood Allogeneic Stem Cell Transplant for Male Recipients

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5878-5878
Author(s):  
Shatha Farhan ◽  
Edward Peres ◽  
Danielle Pelland ◽  
Susan Wautelet ◽  
Klodiana Neme ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Chronic Gvhd ◽  
Unrelated Donor ◽  
Cell Transplant ◽  
Single Center ◽  
Matched Unrelated Donor ◽  
Recipient Age ◽  
Related Donor ◽  
The Impact

Abstract Background: The female donor/male recipient combination increases the risks of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic stem cell transplantation (allo-SCT), with a possible deleterious impact on overall survival (OS). The mammalian Y chromosome encodes male-specific minor histocompatibility (H-Y) antigens that are recognized by female T cells. Some clinical data suggest a strong correlation between H-Y Antigen disparity and GVHD. In addition, female donors are notorious for bearing memory type lymphocytes induced by previous pregnancies; such allo-immune cells may provoke unwanted immune reactions such as GVHD in the recipient. To explore the impact of Female related donor (F-MRD) versus male matched unrelated donor (M-MUD) on outcome of peripheral blood allo-SCT in male recipients, we undertook a single center retrospective analysis of male adult patients transplanted at our center in the last 10 years. MUDs were matched at the allele level for HLA-A, B, C, DRB1, and DQB1. We excluded patients who received donor lymphocyte infusion post SCT. Methods: Disease-free survival (DFS) and OS were calculated using the Kaplan-Meier estimate. Cumulative incidences (CI) were used for relapse (REL), and GVHD in a competing risks setting, NRM being a competing event for REL, and death for GVHD. The following variables were considered: recipient age (³ vs < 57 years, median age), F-MRD vs M-MUD, myeloablative (MAC) vs reduced-intensity ablative conditioning (Red ABL) vs non-myeloablative (NMA) regimen, early (CR1 or PR1 or chronic phase or untreated) vs advanced disease. Steroid-refractory (SR) GVHD was defined as acute GVHD progressing after 3 days of treatment, or unchanged after 7 days, or in incomplete response after 14 days, or chronic GVHD with no response after one month, no partial response after 2 months or progressive disease in 2 weeks of initiation of steroid treatment or during the methylprednisolone taper. RESULTS: Fifty-six patients were identified and included in this analysis. The median age at transplant was 57 years (19-73). Diseases were AML (n=21), ALL (n=7), NHL (n=9), Hodgkin's disease (n=1), myeloma (n=5), MDS (n=11), CLL (n=1), and CML (n=1). Conditioning regimens were MAC (n=35), RED ABL (n=17) or NMA (n=4). Donors were F- MRD (n=24) or M-MUD (n=32). Source of stem cells was peripheral blood in all patients. GVHD prophylaxis consisted of tacrolimus and methotrexate in MRD and tacrolimus, methotrexate and anti-thymocyte globulin in MUD. Of the female donors, 63% had previous pregnancies before donation, 8% had no pregnancies and 29% were unknown. Mean age of female donors was 48 while the mean age for male donors was 35. The median follow-up was 8 months (0.8-54 months). The median OS for patients who received M-MUD was 8.1 months while it was 14.2 months for patients who received F-MRD (p= 0.72) Fig1. Median DFS for patients who received M-MUD was 6 months while it was 7.2 months for patients who received F-MRD (p= 0.94). The CI rates of aGVHD III-IV, extensive chronic GVHD, REL and NRM at 12 months in M-MUD vs F-MRD were 13% vs 16% (p=0.69), 21% vs 27% (p=0.61), 38% vs 44% (P=0.65), and 16% vs 14% (p=0.79), respectively. The CI of SR GVHD in M-MUD vs F-MRD was 24% vs 32% (The Hazard Ratio of srGVHD in M-MUD vs F-MRD is 0.711 (95% confidence interval is 0.29-1.72, p=0.45)) Fig2. Other variables considered in univariate analysis for SR GVHD were recipient age (p=0.55), disease status (p= 0.64), MAC vs other regimens (p=0.58). Conclusion: In this small cohort of consecutive patients from a single center, we found that compared to M-MUD, F-MRD had a trend for higher rates of SR GVHD after peripheral blood allo-SCT in adult male patients, although not statistically significant. There was no impact of F-MRD compared to M-MUD on OS, DFS, REL, NRM or rates of acute or chronic GVHD. However, the absence of statistical impact should be interpreted with caution given the retrospective design of the study and because we cannot exclude a possible limiting effect of a small number of patients. Fig 1 Figure 1 Figure 1. Fig 2 Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document